Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1948 3
1949 2
1950 1
1951 5
1952 6
1953 8
1954 5
1955 3
1956 3
1957 12
1958 9
1959 7
1960 8
1961 12
1962 16
1963 12
1964 6
1965 12
1966 14
1967 23
1968 21
1969 23
1970 24
1971 26
1972 20
1973 25
1974 20
1975 28
1976 22
1977 29
1978 29
1979 28
1980 21
1981 27
1982 24
1983 28
1984 29
1985 28
1986 24
1987 24
1988 19
1989 30
1990 29
1991 27
1992 34
1993 44
1994 41
1995 33
1996 28
1997 32
1998 24
1999 31
2000 36
2001 35
2002 34
2003 45
2004 62
2005 78
2006 70
2007 54
2008 62
2009 86
2010 92
2011 78
2012 69
2013 99
2014 121
2015 108
2016 101
2017 122
2018 157
2019 138
2020 154
2021 183
2022 153
2023 169
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

3,114 results

Results by year

Filters applied: . Clear all
Page 1
Challenges in neoantigen-directed therapeutics.
Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, van der Burg SH, Ott PA, Bogaert C. Lybaert L, et al. Among authors: feldman sa. Cancer Cell. 2023 Jan 9;41(1):15-40. doi: 10.1016/j.ccell.2022.10.013. Epub 2022 Nov 10. Cancer Cell. 2023. PMID: 36368320 Free article. Review.
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z, Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J, Reschke A, Nie EH, Chau IJ, Rotiroti MC, Mount CW, Baggott C, Mavroukakis S, Egeler E, Moon J, Erickson C, Green S, Kunicki M, Fujimoto M, Ehlinger Z, Reynolds W, Kurra S, Warren KE, Prabhu S, Vogel H, Rasmussen L, Cornell TT, Partap S, Fisher PG, Campen CJ, Filbin MG, Grant G, Sahaf B, Davis KL, Feldman SA, Mackall CL, Monje M. Majzner RG, et al. Among authors: feldman sa. Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7. Nature. 2022. PMID: 35130560 Free PMC article. Clinical Trial.
Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Abou-El-Enein M, et al. Among authors: feldman sa. Blood Cancer Discov. 2021 Sep;2(5):408-422. doi: 10.1158/2643-3230.BCD-21-0084. Epub 2021 Aug 3. Blood Cancer Discov. 2021. PMID: 34568831 Free PMC article. Review.
Side effect jiu-jitsu.
Chandy R, Keith KL, Feldman SR. Chandy R, et al. Among authors: feldman sr. J Dermatolog Treat. 2022 Dec;33(8):2151863. doi: 10.1080/09546634.2022.2151863. J Dermatolog Treat. 2022. PMID: 36416402 No abstract available.
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy.
Good Z, Spiegel JY, Sahaf B, Malipatlolla MB, Ehlinger ZJ, Kurra S, Desai MH, Reynolds WD, Wong Lin A, Vandris P, Wu F, Prabhu S, Hamilton MP, Tamaresis JS, Hanson PJ, Patel S, Feldman SA, Frank MJ, Baird JH, Muffly L, Claire GK, Craig J, Kong KA, Wagh D, Coller J, Bendall SC, Tibshirani RJ, Plevritis SK, Miklos DB, Mackall CL. Good Z, et al. Among authors: feldman sa. Nat Med. 2022 Sep;28(9):1860-1871. doi: 10.1038/s41591-022-01960-7. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097223 Free PMC article.
Another transition.
Feldman SR, van de Kerkhof PCM. Feldman SR, et al. J Dermatolog Treat. 2022 Feb;33(1):1. doi: 10.1080/09546634.2022.2036409. J Dermatolog Treat. 2022. PMID: 35098858 No abstract available.
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng WK, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB. Spiegel JY, et al. Among authors: feldman s. Nat Med. 2021 Aug;27(8):1419-1431. doi: 10.1038/s41591-021-01436-0. Epub 2021 Jul 26. Nat Med. 2021. PMID: 34312556 Free PMC article. Clinical Trial.
3,114 results